Multivariable analyses of prognostic factors for progression-free survival (PFS) and complete response (CR) with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial Meeting Abstract

  

Authors:	Hassoun, H.; Jacobus, S. J.; Richardson, P. G.; Zonder, J. A.; Voorhees, P. M.; Kaufman, J. L.; Yee, A. J.; Scott, E. C.; Torka, P.; Libby, E.; Reeves, B.; Wang, M. L.; Anderson, L. D. Jr; Milner, C.; Gasparetto, C. J.; Agha, M.; Khan, A.; Hurd, D. D.; Avigan, D.; Costello, C.; Jakubowiak, A.; Lonial, S.; Raje, N.; Medvedova, E.; McCarthy, P. L.; Orlowski, R. Z.; Nadeem, O.; Laubach, J. P.; Pasquini, M. C.; Giralt, S. A.; Masone, K.; Samur, M. K.; Perrot, A.; Moreau, P.; Avet-Loiseau, H.; Weller, E. A.; Munshi, N. C.; Anderson, K. C.
Abstract Title:	Multivariable analyses of prognostic factors for progression-free survival (PFS) and complete response (CR) with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
Meeting Title:	64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	140
Issue:	Suppl. 1
Meeting Dates:	2022 Dec 10-13
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-11-15
Start Page:	4834
End Page:	4838
Language:	English
ACCESSION:	WOS:000893223204376
DOI:	10.1182/blood-2022-162741
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/205067